Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): January 30, 2024

QHSLab, Inc.

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

Nevada		30-1104301
(State of Incorporation)		(I.R.S. Employer Identification No.)

901 Northpoint Parkway Suite 302 West Palm Beach FL 33407		33407
(Address of Principal Executive Offices)		(ZIP Code)

Registrant’s telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		USAQ		N/A

Item 7.01 Regulation FD Disclosure.

On January 30, 2024, QHSLab, Inc. (the “Company”), sent a letter to its shareholders, a copy of which is attached as Exhibit 99.1.

On January 30, 2024, the Company also issued a press release entitled, QHSLab Integrates Digital Medicine Assessments into Prominent Electronic Health Record (EHR) Company. The full text of this press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

By filing this Current Report on Form 8-K and furnishing the information contained herein, we make no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/admin/), Facebook account (https://www.facebook.com/QHSLabs and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

Exhibit No.		Description
99.1		Letter to shareholders date January 30, 2024
99.2		Press Release dated January 30, 2024 - QHSLab Integrates Digital Medicine Assessments into Prominent Electronic Health Record (EHR) Company
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 30, 2024

QHSLab, Inc.

	/s/ Troy Grogan
Name:	Troy Grogan
Title:	CEO and Chairman

Exhibit 99.1

January 30, 2024

Dear Shareholders,

I’m excited to inform you of a significant achievement at QHSLab: our successful integration with athenahealth’s Electronic Medical Record (EMR) system. This milestone marks a pivotal moment in our growth, opening numerous expansion opportunities.

athenahealth, a leading practice management software, supports over 160,000 medical professionals throughout the United States. Our integration with their EMR system enhances our ability to streamline healthcare management and patient care, significantly easing physicians’ administrative tasks and improving patient coordination.

This strategic collaboration showcases QHSLab’s potential to transform healthcare operations and solidifies our position as an essential tool in the industry. It broadens our market reach, diversifies our client base, and propels us closer to positive cash flow. We are committed to continual innovation and market expansion, confident that these efforts will drive growth and increase shareholder value.

What metrics or indicators are we using to measure the success of the athenahealth EMR integration? We’re focusing on key metrics: the rise in user adoption rates among athenahealth EMR users, decreased administrative time for healthcare providers, improved patient satisfaction scores, increased completed assessments, and growth in practice reimbursements.

How does the integration with athenahealth EMR differentiate QHSLab from competitors?

Integrating athenahealth EMR sets QHSLab apart by offering a seamless, efficient solution that simplifies healthcare practice management. Unlike our competitors, our direct integration reduces administrative workload and enables real-time data management, offering a personalized approach to patient care. This distinct feature positions us uniquely in the digital medicine market.

How does this integration impact QHSLab’s financial projections? Integrating athenahealth EMR is expected to reduce physician adoption friction and therefore, increase the number of new providers using the QHSLab platform, leading to higher subscription and Integrated Service Program (ISP) revenues. Additionally, the integration’s efficiency will likely attract more healthcare practices already using the athenahealth EMR, further driving revenue growth. We are also exploring value added revenue streams to this new integration, including our allergy diagnostics and immunotherapy product line, to enhance financial returns.

What are the plans for further expansions or integrations in the future?

Looking ahead, QHSLab is committed to continuous innovation and expansion. We plan to explore integrations with other major EHR systems to broaden our market reach. Additionally, QHSLab is embracing cutting-edge advancements in technology, particularly in the realms of artificial intelligence (AI) and machine learning. We are significantly enhancing our platform's capabilities by incorporating Microsoft Azure's latest cloud technology, including OpenAI's ChatGPT. Furthermore, we have recently begun to develop using Microsoft Fabric's data warehousing and analytics solutions, released in late 2023. This addition allows us to harness advanced data analysis and management capabilities, ensuring efficient handling of large-scale healthcare data. This integration of Azure's cloud computing power, AI insights from ChatGPT, and the robust data warehousing of Microsoft Fabric collectively empowers us to leverage our ever growing database for large-scale analytics. These technological integrations will be pivotable for our ongoing and future product development, bolstering our current capabilities and positioning QHSLab at the forefront of healthcare technology innovation. We are committed to our long-term vision to enhance the quality of life for individuals and populations by using physician-directed digital medicine, point-of-care solutions, and innovative preventive health technologies, with the following three goals 1) improve patient outcomes; 2) decrease unnecessary waste and non-clinical administrative tasks; and 3) boost practice revenue through reimbursable services.

Please get in touch with us if you have questions or would like more information about this integration. Thank you for your support as we continue to shape the future of medicine.

Warm regards,

Troy Grogan

President and CEO

QHSLab, Inc.

www.qhslab.com

Exhibit 99.2

QHSLab Integrates Digital Medicine Assessments into Prominent Electronic Health Record (EHR) Company

This integration allows QHSLab access to more than 160,000 providers that are the exact match for target providers.

WEST PALM BEACH, FL, January 30, 2024 (GLOBE NEWSWIRE) — QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, is proud to announce the seamless integration of its digital medicine assessments with one of the nation’s top Electronic Health Record (EHR) Company. This update demonstrates promising growth for QHSLab in its mission to revolutionize provider workflow and elevate the quality of patient care.

The more than 160,000 providers utilizing this EHR system will now have direct access to QHSLab’s comprehensive suite of digital medicine assessments and monitoring tools, such as self-management patient education interventions designed to offer healthcare providers a comprehensive view of their patient’s total health. As an added benefit, these practitioners will also have point-of-care testing kits for one of today’s most common complaints in general medicine – allergies. With the addition of the AllergiQT™, physicians can confirm a patient’s allergies with an easy in-office allergy skin test in less than 20 minutes.

Key Advantages for Providers and Patients:

Enhanced Efficiency: Providers will now seamlessly access and review patient assessments within the EHR, negating the need to switch between multiple platforms. This integration simplifies workflow, saving crucial time and reducing administrative burdens, providing healthcare professionals with the bandwidth for better patient care.

Informed Decision-Making: Integrating QHSLab’s digital assessments within the EHR guarantees providers immediate access to comprehensive patient data. This empowers clinicians to make well-informed decisions, translating into more personalized and effective patient care plans.

Real-Time Updates: Patient health is dynamic, and QHSLab provides an ongoing snapshot of a patient’s reported feedback and complaints in real time. Patient data remains consistently updated, with changes in QHSLab’s assessments automatically reflected in the EHR. This ensures healthcare providers can access the most current information when making clinical decisions and care coordination treatment plans.

Seamless Collaboration: The integration fosters a collaborative approach to patient care. Providers can easily share and access patient assessments, nurturing a more connected healthcare ecosystem.

Patient Engagement: Through QHSLab’s digital assessments, patients actively engage in their healthcare journey. They can effortlessly complete assessments from their homes, making healthcare more convenient and accessible. This active involvement has the potential to yield superior patient outcomes. QHSLab also offers a suite of reimbursable assessments and interventions that allow practices to sustain themselves with a new revenue stream through the Company’s proven CPT code reimbursement strategy.

Troy Grogan, Chief Executive Officer at QHSLab, expressed his enthusiasm about this integration: “This collaboration represents a significant milestone for QHSLab. By merging our digital medicine services with EHRs of this caliber, we’re redefining how healthcare providers deliver patient care and reaching a broad, new audience for our platform. We’ve demonstrated a proven track record of success over the past 12 months, and this integration sets the stage for the next chapter of growth during 2024 and beyond.”

For more information about QHSLab, please visit www.qhslab.com

About QHSLab, Inc.

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.

Forward-Looking Statements

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Contact:

Olivia Giamanco

QHSLab, Inc.

(929) 379-6503

ir@usaqcorp.com

https://twitter.com/QHSLabInc

Cover	Jan. 30, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 30, 2024
Entity File Number	0-19041
Entity Registrant Name	QHSLab, Inc.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	West Palm Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	USAQ